How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
about
Recent developments in treatment of latent tuberculosis infectionUpdates on the risk factors for latent tuberculosis reactivation and their managementsCost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange programThe ongoing challenge of latent tuberculosisGranulysin-expressing CD4+ T cells as candidate immune marker for tuberculosis during childhood and adolescenceCompletion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinicImpact of DOTS expansion on tuberculosis related outcomes and costs in HaitiTuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysisPersonal and societal health quality lost to tuberculosis.Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysisTuberculosis in patients with haematological malignancies.What We Have Learned and What We Have Missed in Tuberculosis Pathophysiology for a New Vaccine Design: Searching for the "Pink Swan".Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis.Risk factors for treatment default in close contacts with latent tuberculous infection.Saudi guidelines for testing and treatment of latent tuberculosis infectionThe epidemiology of childhood tuberculosis in the Netherlands: still room for prevention.Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in BotswanaNew approaches in the diagnosis and treatment of latent tuberculosis infectionUpdate on cutaneous tuberculosisLatent tuberculosis infection: old problem, new prioritiesCost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.Diagnostic performance of interferon-gamma releasing assay in HIV-infected patients in China.House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.The use of anti-tuberculosis therapy for latent TB infectionSafety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection.Evidence-based clinical guidelines for immigrants and refugees.Tuberculosis: evidence review for newly arriving immigrants and refugees.Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.Close contact investigation of TB in high-burden, low- and middle-income countries.A systematic review of economic evaluations of chemoprophylaxis for tuberculosis.What Is the Share of the Country's Researches in Iran's National Tuberculosis Guideline?Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysisCombinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk StratificationUnderstanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies.Close contact interferon-gamma response to the new PstS1(285-374):CPF10: a preliminary 1-year follow-up study.Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis.Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug usersTargeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico.
P2860
Q24630473-3129A3F8-29F3-4E01-9481-7B64C6D71349Q28073158-BD38C145-4D34-4605-9A0D-4610564C2FD9Q28359547-5115FFA4-71B1-4AEE-93C5-A23951C14CEEQ28386135-81A12EC8-AEA2-461B-9985-0C7E3C6590ABQ28478603-7E4EC7DE-DCC7-4847-A55B-569A86963F10Q28484855-C3222DA8-9AB4-436B-9057-E035ED7FC1ADQ33254073-A602E880-D466-4210-95DB-E868D63E596BQ33340828-F80EF9E9-EF39-4284-8283-C3F348E64A1EQ33427787-EE5EE14B-A6F0-4BD3-80F5-AEB68FDFD83EQ33532816-6D6DAE33-52E8-4D8A-9959-F56108CB11CDQ33568467-9E6814C1-62AF-4581-9FBE-D5C0FEC351D7Q33679240-6325B326-AAE3-44E1-9635-E4EDD458A6EFQ33702764-F1A8FAFE-1791-41A3-8712-F8E079BECBE7Q33768706-04275890-D091-46EE-80D4-C42B38F7DE1EQ33772114-0F5F6C79-2E1E-41EF-BAAA-89FD3D5F8B66Q33796748-EDEDDC02-B97F-441B-8AEE-1B13869799C8Q33889133-EEF48F5F-6EC7-47AE-BB07-DBBC7746E414Q34419185-DA330DFF-4652-45C0-8880-1848B106BD3EQ34504457-8E8FDFA8-9750-4D89-B4A0-0CDFEBD7A101Q34594825-C67BA1B8-1962-4A8F-B409-18455ACADF70Q34672436-47F5B525-CF98-45E2-BFC4-1C4B92724B41Q34926355-154F2AA4-5852-4072-9454-467F10F4205BQ35001048-AFE444C2-9C36-4A10-9E51-00CB8DEE9A86Q35026573-E03957AA-7BDB-4544-8CEE-D98F1D0B9F15Q35107731-0E755821-2A8A-4A3A-AF94-1FC37CFE9463Q35201293-3EDD4187-E77B-42DE-B9F6-B35C3B9F114FQ35201314-82D759AB-F2D7-4367-BEAF-526AE3D37286Q35297467-EFDAF67B-FF74-47F6-B893-D63C5EB6F291Q35443130-ED9FA1E7-8094-443D-8B09-5D39874F2BAAQ35503563-866C4F1A-EABF-4F38-9A7D-609423958DDDQ35639296-0CFEB2EC-1E87-456A-9091-E31B6DCDDB50Q35754209-D08A1AE3-C736-4AD3-92E7-6B4EA6EF291EQ35787450-1C1A5292-A42B-44FC-B9AF-7ADB9A3E5171Q36058870-8D633CE6-76A0-49B1-BC86-D26798617D48Q36128602-C87B277C-FF42-41EC-94CE-BEB052C4ECD0Q36238015-5A895C92-5BC3-4600-B209-69E9A68ED005Q36258046-79B86BDF-1058-4EC3-95C2-462FCC7C44D0Q36844900-533B047B-9C6B-4569-85B4-ED446124C96FQ37088715-17EE448F-052F-4B87-854B-90C69B306B89Q37391001-B6802724-DE09-4265-B7C3-561B7CD8CB41
P2860
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@ast
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@en
type
label
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@ast
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@en
prefLabel
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@ast
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@en
P1476
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
@en
P2093
Comstock GW
P304
P577
1999-10-01T00:00:00Z